Full-Time
Bioproduction Technician
LFB
1,001-5,000 employees
Public health biopharmaceuticals via plasma-derived products
No salary listed
Alès, France
In Person
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to LFB
See people who can refer or advise you
- You hold a two-year post-secondary degree or higher.
- You have 3 to 5 years of experience acquired in a pharmaceutical or biotechnology environment.
- You have knowledge of traceability monitoring software.
- Perform upstream and downstream production operations, including cell culture, flask, roller bottle, and purification activities, and operate automated 50-liter, 250-liter, and 2,000-liter bioreactor installations.
- Perform the in-process controls required for manufacturing, including cell counting, osmolality, conductivity, and pH testing.
- Report deviations and enter them into the software.
- Participate in the analysis of nonconformities and deviations and in impact assessments.
- Participate in optimizing manufacturing and production processes.
- Propose and coordinate corrective and preventive actions.
- Perform actions related to changes, corrective and preventive actions, and deviations.
- Perform transactions in the relevant business software systems.
- Apply compliance and proper-operation rules for equipment and facilities.
LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Courcebœufs, France
Founded
1994
Get referred to LFB
See people who can refer or advise you
Simplify's Take
What believers are saying
- Amber Plasma added 12 Czech centers in 2024, lifting Europlasma to 24 centers.
- Arras began immunoglobulin production in November 2025, expanding supply and market share.
- LFB's 2026 Sartorius collaboration supports biomanufacturing scale-up and process reliability.
What critics are saying
- Lille's Annex 1 GMP remediation caused workshop delays and strained output in 2025.
- Plasma drug shortages persisted into 2026, forcing ANSM-backed substitution guidance for multiple products.
- If Arras or Lille slip again, France's plasma supply dependence becomes LFB's existential weak point.
What makes LFB unique
- State-backed French plasma specialist with full-chain control through Europlasma and Arras.
- Arras opened production in 2024, aiming to triple fractionation capacity by 2025.
- LFB sells 15 medicines across roughly 30 countries in immunology, hemostasis, intensive care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Education allowance
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 6%Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.